International Society

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Retrieved on: 
Donnerstag, Mai 9, 2024
Stem Cells, Biotechnology, Health, General Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Genetics, Science, Clinical Trials, Mantle cell lymphoma, Cancer, International Society, Investment, Cell, Phenotype, Safety, Risk, Pharmacokinetics, Poster, Lymphoproliferative disorders, Depreciation, Cytokine, Partnership, Lymphoma, Biologics license application, ATRA, Follicular lymphoma, CD19, ASH, Epstein–Barr virus, Patient, NHL, LD, Toxicity, BLA, Memory, Workforce, EBV, Biomarker, SLE, Tabelecleucel, Pharmaceutical industry

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2024, recent business highlights, and key upcoming milestones for 2024.
  • “This is anticipated to provide multiple near-term clinical milestones for ATA3219, including initial non-Hodgkin’s lymphoma data expected in the fourth quarter 2024, and initial lupus nephritis data in the first half of 2025, with plans to expand into a new SLE cohort without lymphodepletion.
  • Subjects will receive lymphodepletion treatment followed by ATA3219 at a dose of 40, 80, or 160 x 106 CAR+ T cells.
  • Subjects will receive LD treatment followed by ATA3219 at a dose of 40, 80, 240, or 480 x 106 CAR+ T cells.

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on: 
Donnerstag, Mai 9, 2024
FDA, International Society, Inflammation, Bromide, EDT, Chronic obstructive pulmonary disease, Risk, Safety, Food, Conference call, Research, Conference, Information technology, Disease, PDUFA, Patient, Pharming, Marketing, VRNA, Pharmacoeconomics, Growth, BST, COPD, Pharmaceutical industry

LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.

Key Points: 
  • PDUFA Target Action Date for Ensifentrine of June 26, 2024
    Conference call today at 9:00 a.m. EDT / 2:00 p.m. BST
    LONDON and RALEIGH, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the first quarter ended March 31, 2024, and provides a corporate update.
  • If approved, the Company intends to launch ensifentrine in the US market in the third quarter of 2024.
  • Verona Pharma will host an investment community webcast and conference call at 9:00 a.m. EDT / 2:00 p.m. BST on Thursday, May 9, 2024, to discuss the first quarter 2024 financial results and the corporate update.
  • An electronic copy of the first quarter 2024 results press release will also be made available today on the Company’s website.

BioCryst Presents New Real-world Evidence Showing Significant Reductions in Healthcare Resource Utilization Among Patients with HAE Following Initiation of ORLADEYO® (berotralstat)

Retrieved on: 
Donnerstag, Mai 9, 2024
University, International Society, Poster, BioCryst Pharmaceuticals, LTP, MD, History, Documentation, Hereditary angioedema, Patient, Medicine, HRU, HAE, Pharmacoeconomics, Disease, Pharmaceutical industry

“The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.

Key Points: 
  • “The data presented here represent the first documentation that prescribing ORLADEYO significantly reduces healthcare resource utilization.
  • This outcome provides a compelling argument that ORLADEYO, which is known to be effective in reducing HAE morbidity, is also a cost-effective strategy for patient management.
  • The poster detailed findings from a retrospective real-world study that featured analysis of administrative claims data of patients with HAE in the United States.
  • We look forward to reporting additional real-world evidence that highlights the benefits associated with long-term prophylaxis with ORLADEYO,” said Dr. William Sheridan, chief development officer and interim chief medical officer of BioCryst.

Multi Radiance Medical Renews Long-Term Global Sponsorship With ISELP

Retrieved on: 
Donnerstag, Mai 9, 2024
Veterinary, Other Manufacturing, Medical Devices, Pets, Health Technology, Manufacturing, Biotechnology, General Health, Consumer, Health, Relaxation, FDA, International Society, Veterinarian, Partnership, Light, Limp, DVM, Laser, Anaphylaxis, FEI, Horse, Medical imaging

Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .

Key Points: 
  • Multi Radiance Medical , manufacturer and world-leader in laser and light-based technology, is proud to renew its long-term Global Sponsor partnership with the International Society of Equine Locomotor Pathology (ISELP) .
  • “As a leader in equine laser therapy, it is only fitting that we continue to partner with the highest level of equine veterinarians, and ISELP represents just that,” says Max Kanarsky, President and CEO of Multi Radiance Medical.
  • Kent Allen, DVM, ISELP board member and chair of the USEF Drugs and Medications Committee and Veterinarian Committee, says, "Science-based adjunctive treatments provide alternatives that help reduce drug-related side effects, making Multi Radiance an ideal partner."
  • I’m seeing reduced healing times, and improvements in healing in some cases unresponsive to a conventional approach.”
    To learn more about Multi Radiance and WellVu visit: https://info.multiradiance.com/vet/mrv_iselp

Cache Raises Seed Financing to Advance its Biomolecule Storage Technologies

Retrieved on: 
Dienstag, Mai 7, 2024
Technology, Research, Genetics, Health Technology, Biotechnology, Health, Data Management, Other Science, Science, Pillar, Harvard University, University, Cancer, Cache, International Society, American College, Cell, Laboratory, AUC, Harvard Business School, University Health Network, Biological engineering, Genetic, Software, Biophysical environment, Area studies, Biochemistry, RNA, Doctor of Philosophy, University Medical Center, Pathology, San Francisco Bay Area, Intelligence, ACMG, Stanford University, George Church, Bioethics, Chemistry, Faculty, MIT, MBA, SBIR, Yale School of Management, Temperature, Ageing, National Science Foundation, Dicarboxylic acid, Biology, Medical genetics, Nucleation, Computer data storage

Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.

Key Points: 
  • Cache DNA, Inc. , a life sciences company revolutionizing biological sample and data storage infrastructure, today announced the closing of its seed round.
  • The funds will help power R&D and support commercial development efforts and key partnerships to bring their solutions to market.
  • “Over the past three decades, sequencing technologies have evolved drastically.
  • It feels like every month, a new sequencing method is developed,” says Michael Becich, Cache CEO.

Komodo Health & Partners Present 33 Real-World Evidence Research Studies at ISPOR 2024

Retrieved on: 
Montag, Mai 6, 2024
Technology, Health, Venture Capital, Professional Services, Artificial Intelligence, Oncology, Other Science, Mental Health, Research, Software, Health Technology, Science, COVID-19, Clinical Trials, Komodo, University of Washington, Lennox–Gastaut syndrome, FDA, Public, University, Target, International Society, RWE, Pregnancy, Policy, AI, Prevalence, Colorectal cancer, Myriad Genetics, LGS, Chronic inflammatory demyelinating polyneuropathy, Neutropenia, CRC, Conference, Workflow, REMS, Genetics, Schizophrenia, Takeda Pharmaceutical Company, Mental health, Neurology, RWD, MPH, Patient, Hypertension, Epilepsy, Gestational age, Standard of care, Stillbirth, Pharmacoeconomics, ZS, Merck, ZS Associates, Breast cancer, Mitigation, Pharmaceutical industry

Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.

Key Points: 
  • Komodo Health today announced the publication of 33 new health economics and outcomes research (HEOR) studies using its Healthcare Map and AI-powered technology platform.
  • The studies, to be featured at the 2024 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Global Conference, shed light on important disease trends spanning women’s health, oncology, mental health, hypertension, neurology, and more.
  • Komodo Health researchers studied the differences in patient outcomes for pregnant women who continued or discontinued the use of antidepressants during pregnancy.
  • Komodo Health researchers analyzed whether the COVID-19 pandemic exacerbated inequities in breast cancer care through its impact on breast cancer staging and HCRU.

Evidation Shares Real-World Data on GLP-1 Use and Social Determinants of Health at ISPOR 2024

Retrieved on: 
Montag, Mai 6, 2024
Software, Data Analytics, Internet, General Health, Health, Data Management, Professional Services, Technology, Online, International Society, Abstract, Weight loss, Doctor of Philosophy, Transport, Life, Exercise, Diet, Data collection, Face, Social, Pharmacoeconomics, Walking, Quality of life

Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.

Key Points: 
  • Current GLP-1 users were more likely to have private insurance and to be targeting more significant weight loss.
  • Social Determinants of Health Associated with Delayed Medical Care in an Online Health Community (#EPH199) illuminates critical and persistent barriers to timely medical care from a survey of 203,486 US adults.
  • Almost 5 million Members strong, Evidation rewards users for engaging in healthy activities and contributing to health research.
  • Using Evidation, health researchers can comprehensively characterize and measure disease onset and progression, treatment impact, quality of life, and social determinants of health across diverse populations over longer observation periods.

Takara Bio Launches First Commercial Dissolvable Microfluidic Lentiviral Transduction Enhancer

Retrieved on: 
Montag, Mai 6, 2024
Research, Medical Supplies, Genetics, Health Technology, Biotechnology, Other Health, Health, Other Science, Science, School, University, International Society, North Carolina State University, Cell, Biomedical engineering, Abstract, UCL, Biomedicine, Lentivirus, Booth, Gene, Society, ISCT, Associate, Vaccine

Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.

Key Points: 
  • Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., today announced the launch of the Lenti-X™ Transduction Sponge, a first-to-market dissolvable microfluidic transduction enhancer that innovates in vitro lentivirus-mediated gene delivery techniques.
  • With an easy, walkaway workflow, the Lenti-X Transduction Sponge achieves high transduction efficiency in any cell type, enabling downstream research applications in the gene and cell therapy space.
  • “The Lenti-X Transduction Sponge will transform the viral transduction landscape with its simple yet elegant design,” said Carol Lou, President & CEO of Takara Bio USA.
  • At ISCT, attendees can engage with Takara Bio during the poster presentation (Abstract #1133) and view the Lenti-X Transduction Sponge at Booth #721.

Coeptis Therapeutics to Present its Universal Allogeneic SNAP-CAR NK Cell Therapy at the ISCT 2024

Retrieved on: 
Mittwoch, Mai 8, 2024
SNAP, University, Cancer, International Society, Infection, Cell, Research, Gene, ISCT, Therapy, Autoimmunity, NK

In Q3 of 2023, Coeptis expanded its exclusive license agreement with the University of Pittsburgh for SNAP-CAR to include natural killer (NK) cells.

Key Points: 
  • In Q3 of 2023, Coeptis expanded its exclusive license agreement with the University of Pittsburgh for SNAP-CAR to include natural killer (NK) cells.
  • Backed by research performed in conjunction with the University of Pittsburgh and Deverra Therapeutics, allogeneic CAR NK cells may be a safer, more clinically accessible, and cost-effective cellular therapy than autologous CAR T-cells.
  • Based on the demonstrated successful use of a novel SNAP-CAR technology in T-cells, the Company is developing a first-in-class universal allogeneic SNAP-CAR NK cell.
  • "ISCT 2024 is a prestigious gathering renowned for fostering groundbreaking ideas and innovation," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

DistillerSR Launches Online Courseware for the Pragmatic Application of Scientifically Validated AI to Literature Reviews

Retrieved on: 
Dienstag, Mai 7, 2024
Part, International Society, AI, Collection, Conference, Research, Literature, Booth, Pharmacoeconomics, Inc., Organization, Health, Medical device

OTTAWA, ON, May 7, 2024 /PRNewswire/ -- DistillerSR® Inc., the market leader in AI-enabled literature review automation software and creator of DistillerSR™, today announced the availability of a new AI training module targeted at medical research professionals conducting literature reviews.  Part of an extensive online portal of training and certification modules, called DistillerSR Learn,  Demystifying AI is a training course designed to help literature review practitioners understand AI terminology, the technology that underpins it, its current limitations, and how to use AI successfully in the preparation of regulatory submissions.  The course complements other DistillerSR training content on the platform's core AI capabilities, which help customers dramatically reduce time to market for medical products and health care guidelines.

Key Points: 
  • The course complements other DistillerSR training content on the platform's core AI capabilities, which help customers dramatically reduce time to market for medical products and health care guidelines.
  • "Since 2016, DistillerSR has used fully integrated scientifically validated AI to further automate the literature review process," said Peter O'Blenis, CEO, DistillerSR Inc. "Our accessible and current AI courseware will help research professionals place into context the current AI market hype while providing a pragmatic, responsible approach to the application of AI in critical health research and regulatory submissions.
  • As the AI market rapidly evolves, we will continue to update our courseware offerings to support the ongoing introduction of new AI capabilities for DistillerSR."
  • DistillerSR's training programs are designed to help researchers improve their ability to conduct faster, more accurate literature reviews.